Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PET (positron emission tomography) imaging helps predict risk of stroke:

This article was originally published in Clinica

Executive Summary

US scientists have used an imaging technique to determine which patients with blocked carotid arteries are more likely to suffer a stroke. Positron emission tomography was used to identify a subgroup of patients with the most severe stage of impaired oxygen delivery to the brain. The researchers' results, published in the Journal of the American Medical Association (September 23/30), showed that patients in this subgroup were six times more likely to have an overall stroke and seven times more likely to suffer a stroke on one side of the brain.

You may also be interested in...



Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Falling Sales Force New Priorities At Roche

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.

Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel